Obsidian Therapeutics, Inc.
OBX · Nasdaq · United States
Share price · OBX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when OBX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+44.4%
- 4 Nov 2026-16.9%
Nothing announced by OBX that day or the session before.
Share of unusual movement by asset
For each asset, the share of OBX's own-move activity since 30 Jul 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
OBX-115events and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 17% |
| Other company news (earnings, financing, releases naming no asset) | — | 52% |
| Sessions with no dated event | — | 31% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | IL-15 receptor signalingCell therapy | Non-Small Cell Lung CancerMelanoma |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $28M | $68M+ $148M short-term inv. | $51M-$37M operating cash flow | report ↗ |
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | $0+ $16M short-term inv. | —$0 operating cash flow | report ↗ |
| 2025-Q3 | $0 | $25M | $37M | $28M-$21M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $23M | — | $27M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $86M | $40M+ $40M short-term inv. | $25M-$90M operating cash flow | report ↗ |
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $73M | $50M+ $119M short-term inv. | $21M-$75M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | Reisenauer Mark L · director | Award / grant (derivative) | 75,364 | — | — | Form 4 |
| 2026-08-03 | Jagasia Madan · director, Chief Executive Officer | Award / grant (derivative) | 678,477 | — | — | Form 4 |
| 2026-08-03 | Hari Parameswaran · Chief Medical Officer | Award / grant (derivative) | 331,173 | — | — | Form 4 |
| 2026-08-03 | Feder Julie B · Chief Financial Officer | Award / grant (derivative) | 164,790 | — | — | Form 4 |
| 2026-08-03 | Fardis Maria · director | Award / grant (derivative) | 37,653 | — | — | Form 4 |
| 2026-08-03 | Hagen Heidi · director | Award / grant (derivative) | 37,653 | — | — | Form 4 |
| 2026-08-03 | Barrett Peter · director | Award / grant (derivative) | 37,653 | — | — | Form 4 |
| 2026-08-03 | Jagasia Madan · director, Chief Executive Officer | Award / grant (derivative) | 37,653 | — | — | Form 4 |